Helsinki – June 14, 2021 – MVision AI is excited to announce partnership with the UK and Ireland-based distributor, Xiel ltd. Xiel will be distributing MVision AI’s high-quality, segmentation services throughout the UK and Ireland region.
“I am delighted Xiel has officially partnered with MVision, a company leading the way in AI technology and one we have followed closely for a number of years. AI is a buzz word in our sector at the moment and we are very excited about working with MVision to integrate their leading technology into Radiotherapy departments in the UK and Ireland”, said Jack Knight, Managing Director, Xiel Ltd
This has a high impact on RT treatment because, according to Cancer Research UK, the time between the urgent referral and treatment process can take up to 62 days. Thanks to Xiel’s distribution of MVision AI’s segmentation software, oncologists will be able to receive consistent, cancer radiotherapy treatment planning. MVision’s cutting-edge, segmentation solutions can help improve the efficiency of cancer patient’s radiotherapy.
MVsion’s CEO and co-founder, Mahmudul Hasan, highlighted his delight in this new partnership, stating that, “We have been working on MVision’s state-of-the-art segmentation services for the last three years. A growing number of hospitals have incorporated our services into their radiation oncology departments. Radiation oncologists have found our solutions to be essential, while improving the speed of service to their patients. We look forward to doing the same for UK patients, as our breakthrough solution reaches the UK and Ireland with the help of Xiel.”
If you are interested in learning more about Xiel’s impactful distribution, check out their informative, company website and professional LinkedIn profile.
For more information on our services, contact MVision AI
c/o Terkko Health Hub, Haartmaninkatu 4, 00290 Helsinki, Finland.
Tel: +358 (0) 40 5489 229
Email: info (at) mvision.ai
FOR MEDIA INQUIRES:
+358 40 500 7915; pr (at) mvision.ai
